Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Iron oxide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Iron oxide. Displaying page 1 of 1.
    EudraCT Number: 2014-002455-26 Sponsor Protocol Number: IRON-CMR Start Date*: 2014-09-20
    Sponsor Name:Karolinska Institute
    Full Title: The use of intravenous Iron oxide as a contrast agent for cardiac magnetic resonance imaging.
    Medical condition: Cardiovascular diseases: Acute myocardial infarction, chronic myocardial infarction, myocardial ischemia, myocarditis, diffuse myocardial fibrosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018961-50 Sponsor Protocol Number: AMAG-FER-IDA-302 Start Date*: 2010-07-02
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase III, Randomized, Open-label, Active-Controlled Trial Comparing Ferumoxytol with Iron Sucrose for the Treatment of Iron Deficiency Anemia
    Medical condition: iron deficiency anemia (IDA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022975 Iron deficiency anemia secondary to blood loss (chronic) LLT
    12.1 10022976 Iron deficiency anemia secondary to inadequate dietary iron intake LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) FR (Completed) LT (Completed) DE (Completed) PL (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002952-17 Sponsor Protocol Number: COPDIron Start Date*: 2012-11-12
    Sponsor Name:University of Oxford
    Full Title: Effects of intravenous iron on hypoxic pulmonary responses in COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002053-31 Sponsor Protocol Number: ALEC4005 Start Date*: 2005-08-16
    Sponsor Name:Hammersmith Hospital
    Full Title: To determine the diagnostic accuracy of MRI in detecting lymph node metastases using USPIO (Ultra small super-paramagnetic iron oxide particles) in patients with gynecological malignancy
    Medical condition: Gynaecological malignancies
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005459-41 Sponsor Protocol Number: ferucarbotran in Pz. con melanoma Start Date*: 2007-09-17
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: Study of superficial lynmph nodes whit superparamagnetic contrast and RMN in patient affected by melanoma.
    Medical condition: melanomas of limbs.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025650 Malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004567-29 Sponsor Protocol Number: RADSIN1 Start Date*: 2004-11-22
    Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
    Full Title: Pelvic lymph node metastases from bladder and prostate cancer magnetic resonance imaging with ultrasmall superparamagnetic iron oxyde sinerem.
    Medical condition: SUSPECT LYMPHONODAL METASTASES
    Disease: Version SOC Term Classification Code Term Level
    6.1 10036909 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001337-17 Sponsor Protocol Number: msuspio1muc Start Date*: 2007-09-25
    Sponsor Name:Max-Planck-Institute of Psychiatry
    Full Title: Characterisation of multiple sclerosis pathology by “ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques [Charakterisierung der Multipl...
    Medical condition: Patients with Multiple Sclerosis (MS, N=90) and patients with a clinically isolated syndrome (ref. to as CIS in literature, i. e. not a clinically definite MS but a syndrome that may occur as first...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028245 Multiple sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002225-19 Sponsor Protocol Number: FE001 Start Date*: 2016-01-18
    Sponsor Name:Diagnostic Centre of Pécs
    Full Title: Ferumoxytol as an MR contrast agent in CNS and head & neck tumors, intracranial and peripheral vascular disease
    Medical condition: Feraheme will be tested as an MRI contrast agent in the diseases of the central nervous system, in head and neck tumors and peripheral vascular diseases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019388-12 Sponsor Protocol Number: AMAG-FER-CKD-252 Start Date*: 2011-05-12
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subje...
    Medical condition: Nondialysis dependent Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) RO (Ongoing) LT (Prematurely Ended) ES (Temporarily Halted) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019387-37 Sponsor Protocol Number: AMAG-FER-CKD-251 Start Date*: 2011-05-11
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subje...
    Medical condition: Dialysis dependent Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) GB (Prematurely Ended) HU (Completed) ES (Completed) RO (Ongoing) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002448-25 Sponsor Protocol Number: MA3RSTrial Start Date*: 2012-10-02
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian Health Board
    Full Title: Magnetic Resonance Imaging Using Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients Under Surveillance for Abdominal Aortic Aneurysms to Predict Rupture or Surgical Repair: the MA3RS ...
    Medical condition: Abdominal Aortic Aneurysm
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-003779-32 Sponsor Protocol Number: NL77171.091.21 Start Date*: 2021-09-27
    Sponsor Name:Radboud University Medical Center
    Full Title: HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study).
    Medical condition: men with biochemical recurrent prostate cancer after radical prostatectomy with ≤ 4 foci harbouring regional lymph node metastases (up to 6 lymph nodes in total) on nano-MRI.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019550-40 Sponsor Protocol Number: AMAG-FER-CKD-253 Start Date*: Information not available in EudraCT
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) HU (Completed) ES (Completed) RO (Temporarily Halted) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005447-25 Sponsor Protocol Number: INTIMA Start Date*: 2013-02-22
    Sponsor Name:Academic Medical Center Amsterdam, department of Internal Medicine
    Full Title: The use of Rienso, an ultrasmall superparamagnetic particle of iron-oxide, as a MRI contrast agent to image inflammation in the atherosclerotic plaque
    Medical condition: Atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005703-42 Sponsor Protocol Number: TMT106468 Start Date*: 2006-03-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 12 week, randomised, double blind study evaluating the effects of low dose (10mg) and high dose (80mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by Ultra s...
    Medical condition: Atherosclerotic Carotid Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008936-10 Sponsor Protocol Number: NIMINI-1/2 Start Date*: 2009-03-16
    Sponsor Name:Division of Cardiology, Robert-Bosch-Krankenhaus
    Full Title: Comparative evaluation of different CMR pulse-sequences with respect to their practicability and diagnostic performance in diagnosing the inflamed myocardium in patients with acute myocardial infar...
    Medical condition: Patients with acute myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000891 Acute myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003544-20 Sponsor Protocol Number: 207972 Start Date*: 2018-02-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A double blind (sponsor open) placebo-controlled, stratified, parallel group study to evaluate the efficacy and safety of repeat doses of GSK3772847 in participants with moderate to severe asthma w...
    Medical condition: asthma with allergic fungal airway disease (AFAD).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014415-12 Sponsor Protocol Number: MEA112997 Start Date*: 2010-01-04
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled ref...
    Medical condition: severe uncontrolled refractory asthma.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:46:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA